Beacon Harbor Wealth Advisors Inc. Takes Position in Medtronic PLC $MDT

Key Points

• Beacon Harbor Wealth Advisors acquired a new stake of 68,951 Medtronic shares in Q4, valued at about $6.62 million, with institutional investors owning roughly 82.06% of the company.
• Insider sale: EVP Harry Skip Kiil sold 52,524 shares on Feb. 19 at an average of $97.71 for ~$5.13 million, cutting his holding by 61.58% (insiders own ~0.26% of shares).
• Earnings and outlook: Medtronic beat quarterly estimates with $1.36 EPS and $9.02B revenue (+5.8% YoY), set FY2026 guidance of $5.62–$5.66 EPS, announced a $0.71 quarterly dividend (3.3% yield), and has an average analyst target of $109 (Moderate Buy).

Beacon Harbor Wealth Advisors Inc. acquired a new stake in Medtronic PLC (NYSE:MDT - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 68,951 shares of the medical technology company's stock, valued at approximately $6,623,000.

Other hedge funds also recently made changes to their positions in the company. Artisan Partners Limited Partnership raised its stake in shares of Medtronic by 2.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company's stock valued at $117,579,000 after buying an additional 31,314 shares in the last quarter. SageView Advisory Group LLC raised its stake in shares of Medtronic by 164.8% in the 3rd quarter. SageView Advisory Group LLC now owns 24,204 shares of the medical technology company's stock valued at $2,305,000 after buying an additional 15,062 shares in the last quarter. CSM Advisors LLC raised its stake in shares of Medtronic by 13.2% in the 3rd quarter. CSM Advisors LLC now owns 285,260 shares of the medical technology company's stock valued at $27,169,000 after buying an additional 33,167 shares in the last quarter. UMB Bank n.a. grew its holdings in shares of Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company's stock worth $13,170,000 after purchasing an additional 54,898 shares during the last quarter. Finally, Applied Finance Capital Management LLC bought a new stake in shares of Medtronic in the 3rd quarter worth about $1,308,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president owned 32,768 shares of the company's stock, valued at $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Medtronic Stock Down 0.8%

Shares of NYSE:MDT opened at $87.17 on Friday. Medtronic PLC has a 12 month low of $79.93 and a 12 month high of $106.33. The company's 50-day moving average price is $93.08 and its two-hundred day moving average price is $95.97. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57. The firm has a market cap of $111.91 billion, a P/E ratio of 24.28, a P/E/G ratio of 2.26 and a beta of 0.75.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts' consensus estimates of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. During the same quarter in the prior year, the firm earned $1.38 EPS. The company's revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be issued a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.3%. Medtronic's dividend payout ratio is currently 79.11%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of Medtronic from a "buy" rating to a "hold" rating in a report on Saturday. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of Medtronic in a report on Monday, December 29th. Wells Fargo & Company assumed coverage on shares of Medtronic in a report on Friday, January 30th. They issued an "overweight" rating and a $114.00 target price on the stock. Robert W. Baird lowered their target price on shares of Medtronic from $103.00 to $100.00 and set a "neutral" rating on the stock in a report on Wednesday, February 18th. Finally, CICC Research assumed coverage on shares of Medtronic in a report on Friday, January 30th. They issued an "outperform" rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $109.00.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.